Article
Generally speaking, for Stage 2 of meaningful use, the bar has been raised; the threshold for measures is higher than it was in Stage 1.
Anktiva as a lymphocyte rescue molecule: Unlocking the power of NK cells and T cells
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
FDA Updates in Urology: January 2025
Phase 2 trial launches of opaganib plus darolutamide in mCRPC